Clinical pharmacogenetic aspects of thymo- and neuroleptic drug treatment

M.-L. Dahl

doi:10.1016/S0924-9338(02)80070-0

Last updated 10th July 2024: Online ordering is currently unavailable due to technical issues. We apologise for any delays responding to customers while we resolve this. For further updates please visit our website https://www.cambridge.org/news-and-insights/technical-incident

Skip to main content Accessibility help

Clinical pharmacogenetic aspects of thymo- and neuroleptic drug treatment

Published online by Cambridge University Press: 16 April 2020

M.-L. Dahl

Show author details

M.-L. Dahl*: Affiliation:
Uppsala University, Department of Medical Sciences, Clinical Pharmacology, Sweden

Article contents

Abstract

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Symposia
Information: European Psychiatry , Volume 17 , Issue S1 , May 2002 , pp. 14s

DOI: https://doi.org/10.1016/S0924-9338(02)80070-0 [Opens in a new window]
Copyright: Copyright © Elsevier, Paris 2002

Submit a response

Comments

No Comments have been published for this article.

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Clinical pharmacogenetic aspects of thymo- and neuroleptic drug treatment

Volume 17, Issue S1
M.-L. Dahl ^(a1)
DOI: https://doi.org/10.1016/S0924-9338(02)80070-0

Your Kindle email address

@free.kindle.com @kindle.com (service fees apply)

Available formats PDF

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

Reply to: Submit a response

Title * Please enter a title for your response.

Contents * Please enter your response.

Your details

First name * Please enter your first name.

Last name * Please enter your last name.

Please enter a valid email address.

Occupation Please enter your occupation.

Affiliation Please enter any affiliation.

You have entered the maximum number of contributors

Conflicting interests

Do you have any conflicting interests? * Conflicting interests help

Yes No

More information * Please enter details of the conflict of interest or select 'No'.

Please tick the box to confirm you agree to our Terms of use. *

Please accept terms of use.

Please tick the box to confirm you agree that your name, comment and conflicts of interest (if accepted) will be visible on the website and your comment may be printed in the journal at the Editor’s discretion. *

Please confirm you agree that your details will be displayed.

Article contents

Clinical pharmacogenetic aspects of thymo- and neuroleptic drug treatment

Abstract

Comments

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests